Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luc G T Morris

Showing results (11-20 of 191) with videos related to

Pageof 20
Sort By:
Cancer|January 6, 2015
Therapeutic targeting of tumor suppressor genesLuc G T Morris, Timothy A Chan
Oncotarget|January 18, 2012
Resistance to EGFR inhibitors: molecular determinants and the enigma of head and neck cancerLuc G T Morris, Timothy A Chan
Translational Cancer Research|March 14, 2023
CD66b as a prognostic and predictive biomarker in patients with non-small cell lung cancer treated with checkpoint blockade immunotherapySwati Jain, Kevin Ma, Luc G T Morris
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery|April 29, 2008
Single-stage BAHA implantation in adults and children: is it safe?Darius Kohan, Luc G T Morris, Thomas Romo
Oncotarget|April 19, 2021
The role of immune surveillance in malignant transformation of benign salivary gland tumorsMaximilian Linxweiler, Jingming Wang, Luc G T Morris
JAMA Oncology|June 27, 2024
Assessing the Evidence for Circulating Tumor HPV DNA in Patients With Oropharyngeal CancerNancy Y Lee, Luc G T Morris, Maximilian Diehn
ANZ Journal of Surgery|July 13, 2010
Blood clot cast of the tracheobronchial treeLuc G T Morris, Mike Sheu, Daniel M Zeitler
JAMA Oncology|June 10, 2021
Inappropriate Use of the Same Cutoff by Different Sequencing Panels for Tumor Mutation Burden as Immunotherapy Biomarker-ReplyCristina Valero, Timothy A Chan, Luc G T Morris
Cell Cycle (Georgetown, Tex.)|March 16, 2013
The FAT epidemic: a gene family frequently mutated across multiple human cancer typesLuc G T Morris, Deepa Ramaswami, Timothy A Chan
Translational Cancer Research|March 12, 2026
Improving stratification in HPV-negative head and neck squamous cell carcinoma (HNSCC) using emerging immune-based biomarkersJustin M Hintze, Siqi Chen, Luc G T Morris
Pageof 20

Showing results (11-20 of 191) with videos related to

Sort By:
Pageof 20
Cancer|January 6, 2015
Therapeutic targeting of tumor suppressor genesLuc G T Morris, Timothy A Chan
Oncotarget|January 18, 2012
Resistance to EGFR inhibitors: molecular determinants and the enigma of head and neck cancerLuc G T Morris, Timothy A Chan
Translational Cancer Research|March 14, 2023
CD66b as a prognostic and predictive biomarker in patients with non-small cell lung cancer treated with checkpoint blockade immunotherapySwati Jain, Kevin Ma, Luc G T Morris
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery|April 29, 2008
Single-stage BAHA implantation in adults and children: is it safe?Darius Kohan, Luc G T Morris, Thomas Romo
Oncotarget|April 19, 2021
The role of immune surveillance in malignant transformation of benign salivary gland tumorsMaximilian Linxweiler, Jingming Wang, Luc G T Morris
JAMA Oncology|June 27, 2024
Assessing the Evidence for Circulating Tumor HPV DNA in Patients With Oropharyngeal CancerNancy Y Lee, Luc G T Morris, Maximilian Diehn
ANZ Journal of Surgery|July 13, 2010
Blood clot cast of the tracheobronchial treeLuc G T Morris, Mike Sheu, Daniel M Zeitler
JAMA Oncology|June 10, 2021
Inappropriate Use of the Same Cutoff by Different Sequencing Panels for Tumor Mutation Burden as Immunotherapy Biomarker-ReplyCristina Valero, Timothy A Chan, Luc G T Morris
Cell Cycle (Georgetown, Tex.)|March 16, 2013
The FAT epidemic: a gene family frequently mutated across multiple human cancer typesLuc G T Morris, Deepa Ramaswami, Timothy A Chan
Translational Cancer Research|March 12, 2026
Improving stratification in HPV-negative head and neck squamous cell carcinoma (HNSCC) using emerging immune-based biomarkersJustin M Hintze, Siqi Chen, Luc G T Morris
Pageof 20